Lunsumio Archives - Medical Design Sourcing

Genentech on how Lunsumio could shift the treatment landscape for R/R FL

In late 2022, the FDA approved Genentech‘s Lunsumio (mosunetuzumab-axgb), a bispecific antibody for relapsed or refractory follicular lymphoma (R/R FL) patients who have received at least two prior systemic therapies.

We recently caught up with Ginna Laport, VP, global head of lymphoma/CLL development franchise at Genentech, to learn more about how the drug could change the treatment landscape for relapsed or refractory follicular lymphoma.

In the following interview, Laport also shares the background story of Lunsumio and Genentech’s plans to continue investigating Lusumio as a monotherapy and in combination with other medicines for blood cancers.

What is your view on how the approval of Lunsumio will change the treatment landscape for relapsed or refractory follicular lymphoma?

Ginna Laport

Laport: Before I joined Genentech, I spent nearly 20 years treating patients with follicular lymphoma (…

Genentech on how Lunsumio could shift the treatment landscape for R/R FL

In late 2022, the FDA approved Genentech‘s Lunsumio (mosunetuzumab-axgb), a bispecific antibody for relapsed or refractory follicular lymphoma (R/R FL) patients who have received at least two prior systemic therapies.

We recently caught up with Ginna Laport, VP, global head of lymphoma/CLL development franchise at Genentech, to learn more about how the drug could change the treatment landscape for relapsed or refractory follicular lymphoma.

In the following interview, Laport also shares the background story of Lunsumio and Genentech’s plans to continue investigating Lusumio as a monotherapy and in combination with other medicines for blood cancers.

What is your view on how the approval of Lunsumio will change the treatment landscape for relapsed or refractory follicular lymphoma?

Ginna Laport

Laport: Before I joined Genentech, I spent nearly 20 years treating patients with follicular lymphoma (…

Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma

Roche (SIX:RO, ROG; OTCQX:RHHBY) has announced that it has accepted the company’s Biologics License Application (BLA) and granted priority review for Lunsumio (mosunetuzumab), a CD20xCD3 T-cell engaging bispecific antibody developed by the company’s Genentech subsidiary.

In February, Biogen (Nasdaq:BIIB) said it would pay $30 million to exercise an option to participate in the development and commercialization of the drug candidate.

Basel, Switzerland-based Roche believes mosunetuzumab holds potential for adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two other systemic therapies.

Follicular lymphoma arises from B-lymphocytes and is a common slow-growing form of non-Hodgkin lymphoma (NHL).

Approximately one in five patients with follicular lymphoma relapse within two years of diagnosis, according to an article in the ASCO Post.

Lunsumio would be a fixed-duration treatment that could …